ISDA: 6A3N

Deposition Date 2018-06-15

Release Date 2019-04-10

Last Version Date 2024-10-16

Entry Detail

PDB ID:

6A3N

Keywords:

HYDROLASE

Title:

Crystal structure of the PDE9 catalytic domain in complex with inhibitor 2

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Escherichia coli bl21

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.60 Å

R-Value Free:

0.28

R-Value Work:

0.24

R-Value Observed:

0.24

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
Gene (Uniprot):PDE9A
Chain IDs:A, B
Chain Length:322
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O76083 Pfam ID:PF00233 EC:3.1.4.35

Ligand Molecules

9Q9

Primary Citation

Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.

Wu, Y, Zhou, Q, Zhang, T, Li, Z, Chen, Y.P, Zhang, P, Yu, Y.F, Geng, H, Tian, Y.J, Zhang, C, Wang, Y, Chen, J.W, Chen, Y, Luo, H.B.Show

J. Med. Chem. 62 4218 4224 (2019)

PMID: 30916555 DOI: 10.1021/acs.jmedchem.8b01041

Abstact

To identify phosphodiesterase-9 (PDE9) as a novel target for the treatment of vascular dementia (VaD), a series of pyrazolopyrimidinone analogues were discovered based on a hit 1. Hit-to-lead optimization resulted in a potent inhibitor 2 with excellent selectivity and physicochemical properties to enable in vivo studies. Oral administration of 2 (5.0 mg/kg) caused notable therapeutic effects in the VaD mouse model, providing a promising lead or chemical probe for investigating the biological functions of PDE9 inhibition.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form